Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano Buys 3,605 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano acquired 3,605 shares of Precision BioSciences stock in a transaction dated Monday, December 30th. The shares were purchased at an average cost of $4.49 per share, with a total value of $16,186.45. Following the completion of the transaction, the director now directly owns 7,807 shares of the company’s stock, valued at $35,053.43. This trade represents a 85.79 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Precision BioSciences Stock Up 1.3 %

DTIL stock opened at $4.75 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The stock has a market capitalization of $36.44 million, a P/E ratio of 79.18 and a beta of 1.41. The business has a 50-day moving average of $6.44 and a 200-day moving average of $8.44. Precision BioSciences, Inc. has a fifty-two week low of $3.61 and a fifty-two week high of $19.43.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC lifted its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 702,069 shares of the company’s stock after buying an additional 68,943 shares during the period. Janus Henderson Group PLC owned about 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.